Vasopeptidase inhibitors: an emerging class of cardiovascular drugs

被引：45

作者：

Bralet, J ^{[1
]}

Schwartz, JC

机构：

[1] Univ Dijon, Fac Pharm, F-21033 Dijon, France

[2] INSERM, Ctr Paul Broca, Inst Univ France, F-75014 Paris, France

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2001年 / 22卷 / 03期

关键词：

D O I：

10.1016/S0165-6147(00)01644-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Vasopeptidase inhibitors (VPIs) inhibit both angiotensin-converting enzyme (ACE) and neprilysin (NEP) and can thus reduce the activity of the renin-angiotensin system and potentiate the vasodilatory, natriuretic and antiproliferative effects of bradykinin and natriuretic peptides, In preclinical studies, VPIs display a large profile being effective in all tested models of hypertension and in heart failure, and ongoing clinical studies suggest th at VPIs possess advantages over other therapies.

引用

页码：106 / 109

页数：6

共 26 条

[11] PROTECTION OF ATRIAL NATRIURETIC FACTOR AGAINST DEGRADATION - DIURETIC AND NATRIURETIC RESPONSES AFTER INVIVO INHIBITION OF ENKEPHALINASE (EC 3.4.24.11) BY ACETORPHAN
GROS, C
SOUQUE, A
SCHWARTZ, JC
DUCHIER, J
COURNOT, A
BAUMER, P
LECOMTE, JM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (19) : 7580 - 7584
[12] DUAL MECHANISM OF ANGIOTENSIN-II INHIBITS ANP-INDUCED MESANGIAL CGMP ACCUMULATION
HANEDA, M
KIKKAWA, R
MAEDA, S
TOGAWA, M
KOYA, D
HORIDE, N
KAJIWARA, N
SHIGETA, Y
[J]. KIDNEY INTERNATIONAL, 1991, 40 (02) : 188 - 194
[13] Hu K, 1999, CARDIOVASC RES, V41, P503
[14] Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
Laurent, S
Boutouyrie, P
Azizi, M
Marie, C
Gros, C
Schwartz, JC
Lecomte, JM
Bralet, J
[J]. HYPERTENSION, 2000, 35 (05) : 1148 - 1153
[15] Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction
Marie, C
Mossiat, C
Gros, C
Schwartz, JC
Lecomte, JM
Bralet, J
[J]. CARDIOVASCULAR RESEARCH, 1999, 41 (03) : 544 - 553
[16] The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
McClean, DR
Ikram, H
Garlick, AH
Richards, AM
Nicholls, MG
Crozier, IG
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) : 479 - 486
[17] The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides
McDowell, G
Coutie, W
Shaw, C
Buchanan, KD
Struthers, AD
Nicholls, DP
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (03) : 329 - 332
[18] Vasopeptidase inhibition and angio-oedema
Messerli, FH
Nussberger, J
[J]. LANCET, 2000, 356 (9230) : 608 - 609
[19] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
Norton, GR
Woodiwiss, AJ
Hartford, C
Trifunovic, B
Middlemost, S
Lee, A
Allen, MJ
[J]. AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (06) : 563 - 571
[20] Plasma bradykinin in angio-oedema
Nussberger, J
Cugno, M
Amstutz, C
Cicardi, M
Pellacani, A
Agostoni, A
[J]. LANCET, 1998, 351 (9117) : 1693 - 1697

← 1 2 3 →